Deadly Deception: Unapproved Weight Loss Peptide Found to be Double the Strength, Exposing Australians to ‘Enormous’ Risk of Overdose
- A vial of unapproved weight loss peptide retatrutide was found to contain nearly double the concentration listed on the label, sparking warnings from health professionals about the ‘enormous’ risk of overdose.
- The peptide, which is currently undergoing clinical trials for the treatment of type 2 diabetes and obesity, is readily available on the black market despite not being approved for human use.
- Doctors have reported multiple cases of life-threatening illness, including acute liver failure, in patients who have taken the peptide, with one woman requiring hospitalization after experiencing severe side effects.
- Experts warn that the unregulated market for peptides poses a significant risk to public health, with many products containing incorrect dosing and contaminants.
Australia’s health professionals are sounding the alarm over the growing trend of using unapproved peptides, particularly among social media influencers and those seeking a quick fix for weight loss.
The latest warning comes after testing revealed that a vial of retatrutide, a weight loss peptide, contained nearly double the concentration listed on the label.
The findings have sparked concerns about the ‘enormous’ risk of overdose, with doctors reporting multiple cases of life-threatening illness in patients who have taken the peptide.
The vial of retatrutide was purchased from an unregulated internet site and tested by a chemical laboratory in Melbourne. The results showed that the peptide contained 19mg of retatrutide, nearly double the labelled concentration of 10mg.
The laboratory also found that the product had a 16.6 per cent purity, with the rest likely to be ‘fill material’, including substances such as mannitol, a sugar that stabilises and protects the active ingredients.
Dr Darcy Holt, a gastroenterologist who has treated patients who have taken high doses of retatrutide, warned that the potential for overdose is ‘enormous’.
“A patient I had seen who took a high dose of retatrutide presented with very serious side effects, including secretory diarrhoea, which could be life-threatening,” he said.
“He could have become so dehydrated with such severe electrolyte abnormalities that he could have died.”
The use of unapproved peptides has been driven by social media influencers promoting their supposed health and beauty benefits, despite safety warnings from authorities.
The Australian Government’s Chief Medical Officer and the Therapeutic Goods Administration have warned Australians not to take unapproved peptides, citing the risk of serious health complications.
Associate research fellow Benjamin Bonenti, who is part of a team researching the harm of unapproved peptides at the University of Queensland, said that the testing revealed a ‘big problem’.
“Double the dose of these types of drugs is a massive difference… it shows the market cannot be taken at face value,” he said.
“We can say that it is exposing people who use peptides to some potentially serious health risks.”
Analysis: What This Means for Australia
The unregulated market for peptides poses a significant risk to public health in Australia. With many products containing incorrect dosing and contaminants, the potential for overdose and serious health complications is high.
The use of unapproved peptides is particularly concerning, as they are often poorly labelled and may contain unknown substances. The Australian Government must take action to regulate the market and ensure that only approved products are available for use.
Experts warn that the growing trend of using unapproved peptides is a ticking time bomb, with the potential for widespread harm. “The risks associated with unapproved peptides are real, and we need to take action to protect the public,” said Dr Holt.
“We need to educate people about the dangers of these products and ensure that only approved products are available for use.”
As the use of unapproved peptides continues to grow, it is essential that the Australian Government takes a proactive approach to regulating the market. This includes increasing public awareness, conducting further testing, and ensuring that only approved products are available for use.
By taking action, we can reduce the risk of serious health complications and protect the public from the dangers of unapproved peptides.
health crisis Therapeutic Goods Administration
